Search

everythinglearnresearchcommunity

for

Search:↓

Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.

A woman developed alopecia after her second Pfizer vaccine but regrew her hair with treatment and had no issues after a booster shot.

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.

A man developed autoimmune symptoms after the Pfizer COVID-19 vaccine, highlighting the need for thorough vaccine safety checks.

Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.

Some people experienced hair loss after COVID-19 vaccination, but it's very rare and vaccines' benefits are greater than this risk.

COVID-19 vaccines have been linked to an increase in hair loss conditions.

A woman experienced sudden hair graying and loss after a COVID-19 vaccine, which improved with treatment.

Scientists made a chemical (compound 4e) that can be applied on skin to reduce oil production, which can help with acne, but it might cause skin sensitivity to light.

Diphenyl ethers can potentially reduce excess oil production when applied on the skin, helping treat conditions like acne.

An 84-year-old man developed severe anemia after his first COVID-19 vaccine shot, improved with treatment, and was advised against a second dose.

Bimatoprost can cause excessive eyelash growth.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.

The document suggests reevaluating the patent system to ensure public benefits from pharmaceutical privileges and to encourage more significant innovations.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.

The conclusion is that measuring how drugs partition into artificial sebum is important for predicting their delivery into hair and sebaceous follicles, and it provides better information than traditional methods.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

High doses of minoxidil can harm marmoset hearts and kidneys, possibly affecting humans similarly.

Chemicals called 4-(alkylthio)- and 4-(arylthio)-benzonitrile derivatives can potentially reduce oil production on skin, which could help treat conditions like acne and hair loss.

A quick and simple method was created to identify minoxidil in hair-growth products using micellar electrokinetic capillary chromatography.

AGA patients have higher rates of metabolic syndrome and carotid atheromatosis, suggesting early screening and prevention is important.

People with early-onset hair loss have higher risk of heart issues, so early screening is important.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Minoxidil promotes hair growth by penetrating skin, with ethanol-containing formulas working best.

Artificial sebum L closely mimics human sebum for drug delivery research.

Oral minoxidil helps hair growth, is cost-effective, and mostly well-tolerated.